{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:03:09Z","timestamp":1791406989626,"version":"4.3.3"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"he Zhejiang Provincial Medical and Health Science and Technology Program","award":["2023KY555"],"award-info":[{"award-number":["2023KY555"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-03351-3","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:42:38Z","timestamp":1761529358000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The role and mechanism of METTL3 in cancer: emerging insights into m6A methylation and therapeutic potential"],"prefix":"10.1186","volume":"30","author":[{"given":"Fang","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangqin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"3351_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3351_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"3351_CR3","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.2174\/1874467213666200810141858","volume":"14","author":"E Papakonstantinou","year":"2021","unstructured":"Papakonstantinou E, Androutsopoulos G, Logotheti S, Adonakis G, Maroulis I, Tzelepi V. DNA methylation in epithelial ovarian cancer: current data and future perspectives. Curr Mol Pharmacol. 2021;14:1013\u201327.","journal-title":"Curr Mol Pharmacol"},{"key":"3351_CR4","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","volume":"13","author":"C Holohan","year":"2013","unstructured":"Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13:714\u201326.","journal-title":"Nat Rev Cancer"},{"key":"3351_CR5","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13045-019-0818-2","volume":"12","author":"ZF Lim","year":"2019","unstructured":"Lim ZF. Ma PC emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. J Hematol Oncol. 2019;12:134.","journal-title":"J Hematol Oncol"},{"key":"3351_CR6","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.cgh.2023.07.027","volume":"22","author":"A Gupta","year":"2024","unstructured":"Gupta A, Peyrin-Biroulet L, Ananthakrishnan AN. Risk of cancer recurrence in patients with immune-mediated diseases with use of immunosuppressive therapies: an updated systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2024;22:499\u2013512.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3351_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2174\/187446720701150105171219","volume":"7","author":"F Sampsonas","year":"2014","unstructured":"Sampsonas F, Ryan D, McPhillips D, Breen DP. Molecular testing and personalized treatment of lung cancer. Curr Mol Pharmacol. 2014;7:22\u201332.","journal-title":"Curr Mol Pharmacol"},{"key":"3351_CR8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2174\/18755488MTEw0NjUbx","volume":"22","author":"Y Hong","year":"2021","unstructured":"Hong Y, Kim WJ. DNA methylation markers in lung cancer. Curr Genomics. 2021;22:79\u201387.","journal-title":"Curr Genomics"},{"key":"3351_CR9","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.tig.2021.06.014","volume":"38","author":"RL Kan","year":"2022","unstructured":"Kan RL, Chen J, Sallam T. Crosstalk between epitranscriptomic and epigenetic mechanisms in gene regulation. Trends Genet. 2022;38:182\u201393.","journal-title":"Trends Genet"},{"key":"3351_CR10","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41568-020-0253-2","volume":"20","author":"I Barbieri","year":"2020","unstructured":"Barbieri I, Kouzarides T. Role of RNA modifications in cancer. Nat Rev Cancer. 2020;20:303\u201322.","journal-title":"Nat Rev Cancer"},{"key":"3351_CR11","doi-asserted-by":"publisher","first-page":"e559","DOI":"10.1002\/mco2.559","volume":"5","author":"G Li","year":"2024","unstructured":"Li G, Yao Q, Liu P, Zhang H, Liu Y, Li S, et al. Critical roles and clinical perspectives of RNA methylation in cancer. MedComm. 2024;5:e559.","journal-title":"MedComm"},{"key":"3351_CR12","doi-asserted-by":"publisher","first-page":"158","DOI":"10.2174\/0113892029296712240405053201","volume":"25","author":"R Mehmood","year":"2024","unstructured":"Mehmood R. Ramifications of m6A Modification on ncRNAs in Cancer. Curr Genomics. 2024;25:158\u201370.","journal-title":"Curr Genomics"},{"key":"3351_CR13","doi-asserted-by":"publisher","first-page":"7239","DOI":"10.1093\/nar\/gkab378","volume":"49","author":"S Oerum","year":"2021","unstructured":"Oerum S, Meynier V, Catala M, Tisn\u00e9 C. A comprehensive review of m6A\/m6Am RNA methyltransferase structures. Nucleic Acids Res. 2021;49:7239\u201355.","journal-title":"Nucleic Acids Res"},{"key":"3351_CR14","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.molcel.2023.01.006","volume":"83","author":"E Sendinc","year":"2023","unstructured":"Sendinc E, Shi Y. RNA m6A methylation across the transcriptome. Mol Cell. 2023;83:428\u201341.","journal-title":"Mol Cell"},{"key":"3351_CR15","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1038\/s41388-024-03184-0","volume":"43","author":"H Xing","year":"2024","unstructured":"Xing H, Gu X, Liu Y, Xu L, He Y, Xue C. NSUN2 regulates Wnt signaling pathway depending on the m5C RNA modification to promote the progression of hepatocellular carcinoma. Oncogene. 2024;43:3469\u201382.","journal-title":"Oncogene"},{"key":"3351_CR16","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1146\/annurev-cellbio-100616-060758","volume":"33","author":"KD Meyer","year":"2017","unstructured":"Meyer KD, Jaffrey SR. Rethinking m(6)A readers, writers, and erasers. Annu Rev Cell Dev Biol. 2017;33:319\u201342.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"3351_CR17","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.molcel.2019.04.025","volume":"74","author":"H Shi","year":"2019","unstructured":"Shi H, Wei J, He C. Where, when, and how: context-dependent functions of RNA methylation writers, readers, and erasers. Mol Cell. 2019;74:640\u201350.","journal-title":"Mol Cell"},{"key":"3351_CR18","doi-asserted-by":"publisher","first-page":"372","DOI":"10.2174\/1389202921999200630144712","volume":"21","author":"DH Pozza","year":"2020","unstructured":"Pozza DH, De Mello RA, Araujo RLC, Velcheti V. Micrornas in lung cancer oncogenesis and tumor suppression: how it can improve the clinical practice? Curr Genomics. 2020;21:372\u201381.","journal-title":"Curr Genomics"},{"key":"3351_CR19","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s41392-022-01175-9","volume":"7","author":"L Cui","year":"2022","unstructured":"Cui L, Ma R, Cai J, Guo C, Chen Z, Yao L, et al. RNA modifications: importance in immune cell biology and related diseases. Signal Transduct Target Ther. 2022;7:334.","journal-title":"Signal Transduct Target Ther"},{"key":"3351_CR20","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1158\/0008-5472.CAN-23-2081","volume":"84","author":"D Chen","year":"2024","unstructured":"Chen D, Ji F, Zhou Q, Cheung H, Pan Y, Lau HC, et al. RUVBL1\/2 blockade targets YTHDF1 activity to suppress m6A-dependent oncogenic translation and colorectal tumorigenesis. Cancer Res. 2024;84:2856\u201372.","journal-title":"Cancer Res"},{"key":"3351_CR21","doi-asserted-by":"publisher","first-page":"103194","DOI":"10.1016\/j.redox.2024.103194","volume":"74","author":"D Wu","year":"2024","unstructured":"Wu D, Spencer CB, Ortoga L, Zhang H, Miao C. Histone lactylation-regulated METTL3 promotes ferroptosis via m6A-modification on ACSL4 in sepsis-associated lung injury. Redox Biol. 2024;74:103194.","journal-title":"Redox Biol"},{"key":"3351_CR22","doi-asserted-by":"publisher","first-page":"112259","DOI":"10.1016\/j.celrep.2023.112259","volume":"42","author":"S Luo","year":"2023","unstructured":"Luo S, Liao C, Zhang L, Ling C, Zhang X, Xie P, et al. METTL3-mediated m6A mRNA methylation regulates neutrophil activation through targeting TLR4 signaling. Cell Rep. 2023;42:112259.","journal-title":"Cell Rep"},{"key":"3351_CR23","doi-asserted-by":"publisher","first-page":"e2412123","DOI":"10.1002\/advs.202412123","volume":"12","author":"Q Yao","year":"2025","unstructured":"Yao Q, Zheng X, Zhang X, Wang Y, Zhou Q, Lv J, et al. METTL3 potentiates M2 macrophage-driven MMT to aggravate renal allograft fibrosis via the TGF-\u03b21\/Smad3 pathway. Adv Sci. 2025;12:e2412123.","journal-title":"Adv Sci"},{"key":"3351_CR24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nchembio.1432","volume":"10","author":"J Liu","year":"2014","unstructured":"Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L, et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. 2014;10:93\u20135.","journal-title":"Nat Chem Biol"},{"key":"3351_CR25","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.molcel.2016.05.041","volume":"63","author":"P Wang","year":"2016","unstructured":"Wang P, Doxtader KA, Nam Y. Structural basis for cooperative function of Mettl3 and Mettl14 methyltransferases. Mol Cell. 2016;63:306\u201317.","journal-title":"Mol Cell"},{"key":"3351_CR26","doi-asserted-by":"publisher","first-page":"e1618","DOI":"10.1002\/wrna.1618","volume":"12","author":"D Garcias Morales","year":"2021","unstructured":"Garcias Morales D, Reyes JL. A birds\u2019-eye view of the activity and specificity of the mRNA m(6) A methyltransferase complex. Wiley Interdiscip Rev RNA. 2021;12:e1618.","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"3351_CR27","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12943-024-02041-8","volume":"23","author":"Y Li","year":"2024","unstructured":"Li Y, Jin H, Li Q, Shi L, Mao Y, Zhao L. The role of RNA methylation in tumor immunity and its potential in immunotherapy. Mol Cancer. 2024;23:130.","journal-title":"Mol Cancer"},{"key":"3351_CR28","doi-asserted-by":"publisher","first-page":"105937","DOI":"10.1016\/j.phrs.2021.105937","volume":"174","author":"B Yang","year":"2021","unstructured":"Yang B, Wang JQ, Tan Y, Yuan R, Chen ZS, Zou C. RNA methylation and cancer treatment. Pharmacol Res. 2021;174:105937.","journal-title":"Pharmacol Res"},{"key":"3351_CR29","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/s41580-019-0168-5","volume":"20","author":"S Zaccara","year":"2019","unstructured":"Zaccara S, Ries RJ, Jaffrey SR. Reading, writing and erasing mRNA methylation. Nat Rev Mol Cell Biol. 2019;20:608\u201324.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3351_CR30","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13045-023-01477-7","volume":"16","author":"YN Qi","year":"2023","unstructured":"Qi YN, Liu Z, Hong LL, Li P, Ling ZQ. Methyltransferase-like proteins in cancer biology and potential therapeutic targeting. J Hematol Oncol. 2023;16:89.","journal-title":"J Hematol Oncol"},{"key":"3351_CR31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/php.12930","volume":"95","author":"M Robinson","year":"2019","unstructured":"Robinson M, Shah P, Cui YH, He YY. The role of dynamic m(6) A RNA methylation in photobiology. Photochem Photobiol. 2019;95:95\u2013104.","journal-title":"Photochem Photobiol"},{"key":"3351_CR32","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/nchembio.687","volume":"7","author":"G Jia","year":"2011","unstructured":"Jia G, Fu Y, Zhao X, Dai Q, Zheng G, Yang Y, et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol. 2011;7:885\u20137.","journal-title":"Nat Chem Biol"},{"key":"3351_CR33","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.tibs.2024.04.001","volume":"49","author":"Z Zou","year":"2024","unstructured":"Zou Z, He C. The YTHDF proteins display distinct cellular functions on m(6)A-modified RNA. Trends Biochem Sci. 2024;49:611\u201321.","journal-title":"Trends Biochem Sci"},{"key":"3351_CR34","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12943-022-01500-4","volume":"21","author":"Y An","year":"2022","unstructured":"An Y, Duan H. The role of m6A RNA methylation in cancer metabolism. Mol Cancer. 2022;21:14.","journal-title":"Mol Cancer"},{"key":"3351_CR35","doi-asserted-by":"publisher","DOI":"10.1172\/JCI177932","author":"Y Ge","year":"2024","unstructured":"Ge Y, Chen R, Ling T, Liu B, Huang J, Cheng Y, et al. Elevated WTAP promotes hyperinflammation by increasing m6A modification in inflammatory disease models. J Clin Invest. 2024. https:\/\/doi.org\/10.1172\/JCI177932.","journal-title":"J Clin Invest"},{"key":"3351_CR36","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.7150\/ijbs.60641","volume":"17","author":"S Qin","year":"2021","unstructured":"Qin S, Mao Y, Wang H, Duan Y, Zhao L. The interplay between m6A modification and non-coding RNA in cancer stemness modulation: mechanisms, signaling pathways, and clinical implications. Int J Biol Sci. 2021;17:2718\u201336.","journal-title":"Int J Biol Sci"},{"key":"3351_CR37","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1136\/gutjnl-2019-319639","volume":"69","author":"Q Wang","year":"2020","unstructured":"Wang Q, Chen C, Ding Q, Zhao Y, Wang Z, Chen J, et al. METTL3-mediated m(6)a modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance. Gut. 2020;69:1193\u2013205.","journal-title":"Gut"},{"key":"3351_CR38","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12943-019-1065-4","volume":"18","author":"B Yue","year":"2019","unstructured":"Yue B, Song C, Yang L, Cui R, Cheng X, Zhang Z, et al. METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer. Mol Cancer. 2019;18:142.","journal-title":"Mol Cancer"},{"key":"3351_CR39","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1038\/s41388-024-03085-2","volume":"43","author":"Y Zang","year":"2024","unstructured":"Zang Y, Tian Z, Wang D, Li Y, Zhang W, Ma C, et al. METTL3-mediated N(6)-methyladenosine modification of STAT5A promotes gastric cancer progression by regulating KLF4. Oncogene. 2024;43:2338\u201354.","journal-title":"Oncogene"},{"key":"3351_CR40","doi-asserted-by":"publisher","first-page":"861807","DOI":"10.3389\/fonc.2022.861807","volume":"12","author":"N Wang","year":"2022","unstructured":"Wang N, Huo X, Zhang B, Chen X, Zhao S, Shi X, et al. METTL3-mediated ADAMTS9 suppression facilitates angiogenesis and carcinogenesis in gastric cancer. Front Oncol. 2022;12:861807.","journal-title":"Front Oncol"},{"key":"3351_CR41","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/s41419-023-06287-w","volume":"14","author":"Y Sun","year":"2023","unstructured":"Sun Y, Gong W, Zhang S. METTL3 promotes colorectal cancer progression through activating JAK1\/STAT3 signaling pathway. Cell Death Dis. 2023;14:765.","journal-title":"Cell Death Dis"},{"key":"3351_CR42","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1053\/j.gastro.2020.11.013","volume":"160","author":"H Chen","year":"2021","unstructured":"Chen H, Gao S, Liu W, Wong CC, Wu J, Wu J, et al. RNA n(6)-methyladenosine methyltransferase METTL3 facilitates colorectal cancer by activating the m(6)a-GLUT1-mTORC1 axis and is a therapeutic target. Gastroenterology. 2021;160:1284-300.e16.","journal-title":"Gastroenterology"},{"key":"3351_CR43","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12943-019-1038-7","volume":"18","author":"T Li","year":"2019","unstructured":"Li T, Hu PS, Zuo Z, Lin JF, Li X, Wu QN, et al. METTL3 facilitates tumor progression via an m(6)A-IGF2BP2-dependent mechanism in colorectal carcinoma. Mol Cancer. 2019;18:112.","journal-title":"Mol Cancer"},{"key":"3351_CR44","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/s13046-019-1408-4","volume":"38","author":"W Peng","year":"2019","unstructured":"Peng W, Li J, Chen R, Gu Q, Yang P, Qian W, et al. Upregulated METTL3 promotes metastasis of colorectal cancer via miR-1246\/SPRED2\/MAPK signaling pathway. J Exp Clin Cancer Res. 2019;38:393.","journal-title":"J Exp Clin Cancer Res"},{"key":"3351_CR45","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1002\/hep.29683","volume":"67","author":"M Chen","year":"2018","unstructured":"Chen M, Wei L, Law CT, Tsang FH, Shen J, Cheng CL, et al. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Hepatology. 2018;67:2254\u201370.","journal-title":"Hepatology"},{"key":"3351_CR46","doi-asserted-by":"publisher","first-page":"216122","DOI":"10.1016\/j.canlet.2023.216122","volume":"559","author":"L Wang","year":"2023","unstructured":"Wang L, Yang Q, Zhou Q, Fang F, Lei K, Liu Z, et al. METTL3-m(6)A-EGFR-axis drives lenvatinib resistance in hepatocellular carcinoma. Cancer Lett. 2023;559:216122.","journal-title":"Cancer Lett"},{"key":"3351_CR47","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/s41417-023-00697-w","volume":"31","author":"J Hu","year":"2024","unstructured":"Hu J, Chen K, Hong F, Gao G, Dai X, Yin H. METTL3 facilitates stemness properties and tumorigenicity of cancer stem cells in hepatocellular carcinoma through the SOCS3\/JAK2\/STAT3 signaling pathway. Cancer Gene Ther. 2024;31:228\u201336.","journal-title":"Cancer Gene Ther"},{"key":"3351_CR48","doi-asserted-by":"publisher","first-page":"216222","DOI":"10.1016\/j.canlet.2023.216222","volume":"565","author":"J Chen","year":"2023","unstructured":"Chen J, Zhang H, Xiu C, Gao C, Wu S, Bai J, et al. Mettl3 promotes pancreatic cancer proliferation and stemness by increasing stability of ID2 mRNA in a m6a-dependent manner. Cancer Lett. 2023;565:216222.","journal-title":"Cancer Lett"},{"key":"3351_CR49","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s12957-022-02743-7","volume":"20","author":"Y Li","year":"2022","unstructured":"Li Y, Huang H, Zhu Y, Xu B, Chen J, Liu Y, et al. Increased expression of METTL3 in pancreatic cancer tissues associates with poor survival of the patients. World J Surg Oncol. 2022;20:283.","journal-title":"World J Surg Oncol"},{"key":"3351_CR50","doi-asserted-by":"publisher","first-page":"152666","DOI":"10.1016\/j.prp.2019.152666","volume":"215","author":"T Xia","year":"2019","unstructured":"Xia T, Wu X, Cao M, Zhang P, Shi G, Zhang J, et al. The RNA m6A methyltransferase METTL3 promotes pancreatic cancer cell proliferation and invasion. Pathol Res Pract. 2019;215:152666.","journal-title":"Pathol Res Pract"},{"key":"3351_CR51","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41419-023-05715-1","volume":"14","author":"C Lin","year":"2023","unstructured":"Lin C, Li T, Wang Y, Lai S, Huang Y, Guo Z, et al. METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation. Cell Death Dis. 2023;14:221.","journal-title":"Cell Death Dis"},{"key":"3351_CR52","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13046-023-02638-9","volume":"42","author":"Y Sun","year":"2023","unstructured":"Sun Y, Shen W, Hu S, Lyu Q, Wang Q, Wei T, et al. METTL3 promotes chemoresistance in small cell lung cancer by inducing mitophagy. J Exp Clin Cancer Res. 2023;42:65.","journal-title":"J Exp Clin Cancer Res"},{"key":"3351_CR53","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12935-021-02433-6","volume":"22","author":"Y Xu","year":"2022","unstructured":"Xu Y, Lv D, Yan C, Su H, Zhang X, Shi Y, et al. METTL3 promotes lung adenocarcinoma tumor growth and inhibits ferroptosis by stabilizing SLC7A11 m(6)A modification. Cancer Cell Int. 2022;22:11.","journal-title":"Cancer Cell Int"},{"key":"3351_CR54","doi-asserted-by":"publisher","first-page":"109876","DOI":"10.1016\/j.abb.2023.109876","volume":"752","author":"B Zhang","year":"2024","unstructured":"Zhang B, Qian R, Li X. METTL3 suppresses invasion of lung cancer via SH3BP5 m6A modification. Arch Biochem Biophys. 2024;752:109876.","journal-title":"Arch Biochem Biophys"},{"key":"3351_CR55","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/s41417-023-00614-1","volume":"30","author":"S Zhao","year":"2023","unstructured":"Zhao S, Song P, Zhou G, Zhang D, Hu Y. METTL3 promotes the malignancy of non-small cell lung cancer by N6-methyladenosine modifying SFRP2. Cancer Gene Ther. 2023;30:1094\u2013104.","journal-title":"Cancer Gene Ther"},{"key":"3351_CR56","doi-asserted-by":"publisher","DOI":"10.3892\/or.2021.8114","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Liu S, Zhao T, Dang C. Mettl3-mediated m6A modification of Bcl-2 mRNA promotes non-small cell lung cancer progression. Oncol Rep. 2021. https:\/\/doi.org\/10.3892\/or.2021.8114.","journal-title":"Oncol Rep"},{"key":"3351_CR57","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1186\/s12967-023-04624-3","volume":"21","author":"Z Wu","year":"2023","unstructured":"Wu Z, Wei N. METTL3-mediated HOTAIRM1 promotes vasculogenic mimicry icontributionsn glioma via regulating IGFBP2 expression. J Transl Med. 2023;21:855.","journal-title":"J Transl Med"},{"key":"3351_CR58","doi-asserted-by":"publisher","first-page":"0324","DOI":"10.34133\/research.0324","volume":"7","author":"Y Yan","year":"2024","unstructured":"Yan Y, Luo A, Liu S, Cai M, Liu X, Zhang X, et al. METTL3-mediated LINC00475 alternative splicing promotes glioma progression by inducing mitochondrial fission. Research. 2024;7:0324.","journal-title":"Research"},{"key":"3351_CR59","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/onc.2017.351","volume":"37","author":"A Visvanathan","year":"2018","unstructured":"Visvanathan A, Patil V, Arora A, Hegde AS, Arivazhagan A, Santosh V, et al. Essential role of METTL3-mediated m(6)A modification in glioma stem-like cells maintenance and radioresistance. Oncogene. 2018;37:522\u201333.","journal-title":"Oncogene"},{"key":"3351_CR60","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.canlet.2021.04.020","volume":"511","author":"YZ Chang","year":"2021","unstructured":"Chang YZ, Chai RC, Pang B, Chang X, An SY, Zhang KN, et al. METTL3 enhances the stability of MALAT1 with the assistance of HuR via m6A modification and activates NF-\u03baB to promote the malignant progression of IDH-wildtype glioma. Cancer Lett. 2021;511:36\u201346.","journal-title":"Cancer Lett"},{"key":"3351_CR61","doi-asserted-by":"publisher","first-page":"7640","DOI":"10.7150\/thno.61178","volume":"11","author":"Y Chen","year":"2021","unstructured":"Chen Y, Pan C, Wang X, Xu D, Ma Y, Hu J, et al. Silencing of METTL3 effectively hinders invasion and metastasis of prostate cancer cells. Theranostics. 2021;11:7640\u201357.","journal-title":"Theranostics"},{"key":"3351_CR62","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1002\/tox.23874","volume":"38","author":"G Li","year":"2023","unstructured":"Li G, Liu J, Wang Y, Liu H, Fu J, Zhao Y, et al. METTL3-mediated m6A modification of pri-miR-148a-3p affects prostate cancer progression by regulating TXNIP. Environ Toxicol. 2023;38:2377\u201390.","journal-title":"Environ Toxicol"},{"key":"3351_CR63","doi-asserted-by":"publisher","first-page":"117366","DOI":"10.1016\/j.biopha.2024.117366","volume":"179","author":"X Chen","year":"2024","unstructured":"Chen X, Wang M, Wang H, Yang J, Li X, Zhang R, et al. Mettl3 inhibitor suppresses the progression of prostate cancer via IGFBP3\/AKT pathway and synergizes with PARP inhibitor. Biomed Pharmacother. 2024;179:117366.","journal-title":"Biomed Pharmacother"},{"key":"3351_CR64","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41419-023-06411-w","volume":"15","author":"Y Chen","year":"2024","unstructured":"Chen Y, He Y, Li Z, Zhang N, Zhou C, He X, et al. METTL3 facilitates renal cell carcinoma progression by PLOD2 m(6)A-methylation under prolonged hypoxia. Cell Death Dis. 2024;15:62.","journal-title":"Cell Death Dis"},{"key":"3351_CR65","doi-asserted-by":"publisher","first-page":"110971","DOI":"10.1016\/j.cellsig.2023.110971","volume":"113","author":"CH Liu","year":"2024","unstructured":"Liu CH, Zhang JJ, Zhang QJ, Dong Y, Shi ZD, Hong SH, et al. METTL3 regulates the proliferation, metastasis and EMT progression of bladder cancer through P3H4. Cell Signal. 2024;113:110971.","journal-title":"Cell Signal"},{"key":"3351_CR66","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12943-019-1036-9","volume":"18","author":"J Han","year":"2019","unstructured":"Han J, Wang JZ, Yang X, Yu H, Zhou R, Lu HC, et al. METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221\/222 maturation in m6A-dependent manner. Mol Cancer. 2019;18:110.","journal-title":"Mol Cancer"},{"key":"3351_CR67","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1038\/s41388-019-0683-z","volume":"38","author":"M Cheng","year":"2019","unstructured":"Cheng M, Sheng L, Gao Q, Xiong Q, Zhang H, Wu M, et al. The m(6)A methyltransferase METTL3 promotes bladder cancer progression via AFF4\/NF-\u03baB\/MYC signaling network. Oncogene. 2019;38:3667\u201380.","journal-title":"Oncogene"},{"key":"3351_CR68","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1016\/j.ymthe.2021.01.019","volume":"29","author":"J He","year":"2021","unstructured":"He J, Zhou M, Yin J, Wan J, Chu J, Jia J, et al. METTL3 restrains papillary thyroid cancer progression via m(6)A\/c-Rel\/IL-8-mediated neutrophil infiltration. Mol Ther. 2021;29:1821\u201337.","journal-title":"Mol Ther"},{"key":"3351_CR69","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.7150\/ijbs.84797","volume":"20","author":"N Kang","year":"2024","unstructured":"Kang N, Zhao Z, Wang Z, Ning J, Wang H, Zhang W, et al. METTL3 regulates thyroid cancer differentiation and chemosensitivity by modulating PAX8. Int J Biol Sci. 2024;20:3426\u201341.","journal-title":"Int J Biol Sci"},{"key":"3351_CR70","doi-asserted-by":"publisher","first-page":"1257410","DOI":"10.3389\/fphar.2023.1257410","volume":"14","author":"Y Wang","year":"2023","unstructured":"Wang Y, Hong Z, Song J, Zhong P, Lin L. METTL3 promotes drug resistance to oxaliplatin in gastric cancer cells through DNA repair pathway. Front Pharmacol. 2023;14:1257410.","journal-title":"Front Pharmacol"},{"key":"3351_CR71","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00018-022-04129-0","volume":"79","author":"H Li","year":"2022","unstructured":"Li H, Wang C, Lan L, Yan L, Li W, Evans I, et al. METTL3 promotes oxaliplatin resistance of gastric cancer CD133+ stem cells by promoting PARP1 mRNA stability. Cell Mol Life Sci. 2022;79:135.","journal-title":"Cell Mol Life Sci"},{"key":"3351_CR72","doi-asserted-by":"publisher","first-page":"101144","DOI":"10.1016\/j.xcrm.2023.101144","volume":"4","author":"Y Pan","year":"2023","unstructured":"Pan Y, Chen H, Zhang X, Liu W, Ding Y, Huang D, et al. METTL3 drives NAFLD-related hepatocellular carcinoma and is a therapeutic target for boosting immunotherapy. Cell Rep Med. 2023;4:101144.","journal-title":"Cell Rep Med"},{"key":"3351_CR73","doi-asserted-by":"publisher","first-page":"110440","DOI":"10.1016\/j.cellsig.2022.110440","volume":"99","author":"Y Tang","year":"2022","unstructured":"Tang Y, Gao G, Xia WW, Wang JB. Mettl3 promotes the growth and metastasis of pancreatic cancer by regulating the m6a modification and stability of E2F5. Cell Signal. 2022;99:110440.","journal-title":"Cell Signal"},{"key":"3351_CR74","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41420-023-01327-y","volume":"9","author":"J Shi","year":"2023","unstructured":"Shi J, Zhang P, Dong X, Yuan J, Li Y, Li S, et al. METTL3 knockdown promotes temozolomide sensitivity of glioma stem cells via decreasing MGMT and APNG mRNA stability. Cell Death Discov. 2023;9:22.","journal-title":"Cell Death Discov"},{"key":"3351_CR75","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1007\/s11010-024-05023-y","volume":"479","author":"P He","year":"2024","unstructured":"He P, Liu X, Yu G, Wang Y, Wang S, Liu J, et al. METTL3 facilitates prostate cancer progression via inducing HOXC6 m6A modification and stabilizing its expression through IGF2BP2-dependent mechanisms. Mol Cell Biochem. 2024;479:1707\u201320.","journal-title":"Mol Cell Biochem"},{"key":"3351_CR76","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41419-023-05773-5","volume":"14","author":"Y Li","year":"2023","unstructured":"Li Y, Zhu S, Chen Y, Ma Q, Kan D, Yu W, et al. Post-transcriptional modification of m(6)A methylase METTL3 regulates ERK-induced androgen-deprived treatment resistance prostate cancer. Cell Death Dis. 2023;14:289.","journal-title":"Cell Death Dis"},{"key":"3351_CR77","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12935-024-03240-5","volume":"24","author":"X Zhou","year":"2024","unstructured":"Zhou X, Chang L, Liang Q, Zhao R, Xiao Y, Xu Z, et al. The m6A methyltransferase METTL3 drives thyroid cancer progression and lymph node metastasis by targeting LINC00894. Cancer Cell Int. 2024;24:47.","journal-title":"Cancer Cell Int"},{"key":"3351_CR78","doi-asserted-by":"publisher","first-page":"4853","DOI":"10.7150\/jca.96760","volume":"15","author":"Y Yu","year":"2024","unstructured":"Yu Y, Hai Y, Zhou H, Bao W, Hu X, Gao Y, et al. METTL3 inhibition suppresses cell growth and survival in colorectal cancer via ASNS downregulation. J Cancer. 2024;15:4853\u201365.","journal-title":"J Cancer"},{"key":"3351_CR79","doi-asserted-by":"publisher","first-page":"4750","DOI":"10.7150\/ijbs.97425","volume":"20","author":"R Zhang","year":"2024","unstructured":"Zhang R, Chen P, Wang Y, Zeng Z, Yang H, Li M, et al. Targeting METTL3 enhances the chemosensitivity of non-small cell lung cancer cells by decreasing ABCC2 expression in an m(6)A-YTHDF1-dependent manner. Int J Biol Sci. 2024;20:4750\u201366.","journal-title":"Int J Biol Sci"},{"key":"3351_CR80","doi-asserted-by":"publisher","first-page":"4243","DOI":"10.1111\/odi.14864","volume":"30","author":"L Liu","year":"2024","unstructured":"Liu L, Zhao T, Zheng S, Tang D, Han H, Yang C, et al. METTL3 inhibitor STM2457 impairs tumor progression and enhances sensitivity to anlotinib in OSCC. Oral Dis. 2024;30:4243\u201354.","journal-title":"Oral Dis"},{"key":"3351_CR81","doi-asserted-by":"publisher","first-page":"8852","DOI":"10.3390\/cimb45110555","volume":"45","author":"S Hao","year":"2023","unstructured":"Hao S, Sun H, Sun H, Zhang B, Ji K, Liu P, et al. STM2457 inhibits the invasion and metastasis of pancreatic cancer by down-regulating BRAF-activated noncoding RNA N6-methyladenosine modification. Curr Issues Mol Biol. 2023;45:8852\u201363.","journal-title":"Curr Issues Mol Biol"},{"key":"3351_CR82","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1021\/acsbiomedchemau.3c00023","volume":"3","author":"RK Bedi","year":"2023","unstructured":"Bedi RK, Huang D, Li Y. Caflisch a structure-based design of inhibitors of the m(6)A-RNA writer enzyme METTL3. ACS Bio Med Chem Au. 2023;3:359\u201370.","journal-title":"ACS Bio Med Chem Au"},{"key":"3351_CR83","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1158\/1541-7786.MCR-24-0362","volume":"23","author":"W Chen","year":"2025","unstructured":"Chen W, Zhang J, Ma W, Liu N, Wu T. METTL3-mediated m6A modification regulates the Polycomb Repressive Complex 1 components BMI1 and RNF2 in hepatocellular carcinoma cells. Mol Cancer Res. 2025;23:190\u2013201.","journal-title":"Mol Cancer Res"},{"key":"3351_CR84","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1021\/acs.jmedchem.4c02225","volume":"68","author":"G Dutheuil","year":"2025","unstructured":"Dutheuil G, Oukoloff K, Korac J, Lenoir F, El Bousmaqui M, Probst N, et al. Discovery, optimization, and preclinical pharmacology of EP652, a METTL3 inhibitor with efficacy in liquid and solid tumor models. J Med Chem. 2025;68:2981\u20133003.","journal-title":"J Med Chem"},{"key":"3351_CR85","doi-asserted-by":"publisher","first-page":"e202402611","DOI":"10.1002\/anie.202402611","volume":"63","author":"Z Li","year":"2024","unstructured":"Li Z, Feng Y, Han H, Jiang X, Chen W, Ma X, et al. A stapled peptide inhibitor targeting the binding interface of N6-adenosine-methyltransferase subunits METTL3 and METTL14 for cancer therapy. Angew Chem Int Ed Engl. 2024;63:e202402611.","journal-title":"Angew Chem Int Ed Engl"},{"key":"3351_CR86","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1111\/jcmm.16114","volume":"25","author":"F Gao","year":"2021","unstructured":"Gao F, Wang Q, Zhang C, Zhang C, Qu T, Zhang J, et al. RNA methyltransferase METTL3 induces intrinsic resistance to gefitinib by combining with MET to regulate PI3K\/AKT pathway in lung adenocarcinoma. J Cell Mol Med. 2021;25:2418\u201325.","journal-title":"J Cell Mol Med"},{"key":"3351_CR87","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1053\/j.gastro.2022.06.024","volume":"163","author":"H Chen","year":"2022","unstructured":"Chen H, Pan Y, Zhou Q, Liang C, Wong CC, Zhou Y, et al. METTL3 inhibits antitumor immunity by targeting m(6)A-BHLHE41-CXCL1\/CXCR2 axis to promote colorectal cancer. Gastroenterology. 2022;163:891\u2013907.","journal-title":"Gastroenterology"},{"key":"3351_CR88","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1007\/s12013-024-01615-z","volume":"83","author":"H Song","year":"2025","unstructured":"Song H, Sun X, Wang X, Xie T, Zheng Z, Ji Y, et al. \u03b2-elemene ameliorates cisplatin resistance of gastric cancer via regulating exosomal METTL3-m6A-ARF6 axis. Cell Biochem Biophys. 2025;83:2047\u201358.","journal-title":"Cell Biochem Biophys"},{"key":"3351_CR89","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41419-023-05840-x","volume":"14","author":"J Dai","year":"2023","unstructured":"Dai J, Qu T, Yin D, Cui Y, Zhang C, Zhang E, et al. LncRNA LINC00969 promotes acquired gefitinib resistance by epigenetically suppressing of NLRP3 at transcriptional and posttranscriptional levels to inhibit pyroptosis in lung cancer. Cell Death Dis. 2023;14:312.","journal-title":"Cell Death Dis"},{"key":"3351_CR90","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41586-021-03536-w","volume":"593","author":"E Yankova","year":"2021","unstructured":"Yankova E, Blackaby W, Albertella M, Rak J, De Braekeleer E, Tsagkogeorga G, et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature. 2021;593:597\u2013601.","journal-title":"Nature"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03351-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-03351-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03351-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:02:31Z","timestamp":1761534151000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-03351-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":90,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3351"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-03351-3","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1017"}}